Roche Pregnancy Care Solutions

One Roche pregnancy care diagnostic solutions offer you an effective and accurate diagnostic and screening solutions. This includes the Elecsys AMH immunoassay, enabling you to conduct fast, fully automated, sensitive and robust measurement of AMH as a reliable source of prognostic information in fertility counseling for an aspiring mother.

Once her pregnancy journey has begun, Roche's Harmony prenatal (NIPT) test examines fragments of the baby's DNA in the mother's blood to provide accurate information about the likelihood of the most common chromosomal conditions as early as 10 weeks into the pregnancy. 

Finally, Roche's Elecsys sFlt-1 and PIGF immunoassays for preeclampsia represent a reliable tool that enables you to confidently identify and closely monitor mothers at high risk of developing the condition, while discharging those that are not likely to develop the disease - both while screening between the first and second trimesters, and then diagnosing and predicting in the second and third trimesters of the pregnancy. 

One Roche pregnancy care diagnostic solutions offer you diagnostic and screening solutions that empower you with the precision you need, being a trusted partner while guiding her on her journey to motherhood with accurate data. Unleash the full value of your lab and drive the transformation of fertility care management through diagnostic breakthroughs and excellent technical performance.

Roche's Elecsys AMH immunoassays provide clinical confidence and enable you to conduct fast, fully automated, sensitive and robust measurement of AMH, as a reliable tool for assessment of ovarian reserve, prediction of response to COS, and individualized dosing of follitropin delta.

Once the pregnancy journey has begun, Roche's Harmony prenatal (NIPT) testing can provide accurate information about the likelihood of the most common chromosomal conditions as early as 10 weeks into the pregnancy. 

Finally, Roche's Elecsys sFlt-1 and PIGF immunoassays for preeclampsia represent a reliable tool that enables you to confidently identify and closely monitor mothers at high risk of developing the condition. Accurate identification of high-risk patients in the first trimester can result in use of prophylactic aspirin, which can lead to reduced incidence of PE. You and your lab can also play an important role in improved accuracy and sensitivity for PE prediction and diagnosis in the second and third trimesters, resulting in a reduction of over-treatment and unnecessary hospitalization.

One Roche pregnancy care diagnostic solutions offer you the ability to optimize your organization's resources, along with the ability to deliver excellence in value-based, personalized pregnancy care throughout her journey to motherhood. Lead by example and drive the transformation of healthcare by making your contribution felt from the earliest stage of the pregnancy with the Elecsys AMH immunoassays, a reliable source of information in fertility counseling for an aspiring mother.

Once her pregnancy journey has begun, Roche's Harmony NIPT found to be better than conventional methods in first trimester screening for the most common chromosomal conditions, as defined by sensitivity, specificity and positive predictive value¹ - represents a global opportunity to improve prenatal testing and protect aspiring mothers by limiting invasive methods that carry a risk of miscarriage. 

Finally, Roche's Elecsys sFlt-1 and PIGF immunoassays for preeclampsia are a reliable and cost-effective tool for first-trimester screening and confident identification of mothers at high risk of developing the condition - a leading cause of maternal and fetal death across the world every year². In the second and third trimesters, Roche's screening methods can improve risk stratification among pregnant women with suspected preeclampsia, potentially improving resource utilization among low-risk patients, and avoiding unnecessary hospitalization ahead of the onset of the disorder.